Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK7XYH)

Drug Name

PF-07284890 Drug Info

Synonyms

Tinlorafenib; ARRY-461; Tinlorafenib [USAN]; PF-07284890; JNJ5N2RH5W; AR00504461; UNII-JNJ5N2RH5W; 2573781-75-4; WHO 12353; 1-Propanesulfonamide, N-(2-chloro-3-((3,4-dihydro-3,5-dimethyl-4-oxo-6-quinazolinyl)amino)-4-fluorophenyl)-3-fluoro-; N-(2-chloro-3-((3,5-dimethyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoropropane-1-sulfonamide; tinlorafenib [INN]; ARRY461; CHEMBL5095256; SCHEMBL22831935; GTPL12096; BDBM565133; EX-A7593; HY-147405; CS-0564141; PF07284890; PF-07284890; ARRY-461; US11414404, Ex. # 10

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 1	[1]

Cross-matching ID

PubChem CID: 155434855
TTD Drug ID: DMK7XYH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serine/threonine-protein kinase B-raf (BRAF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[3]
Vemurafenib	DM62UG5	Melanoma	2C30	Approved	[4]
LGX818	DMNQXV8	Melanoma	2C30	Approved	[5]
PLX8394	DMRTD7I	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
CEP-32496	DMAO04B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
BGB-283	DMVYTG7	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
ARQ 736	DMP9ZT1	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
RO-5212054	DML4C3Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
ASN003	DMJCX6D	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
BMS-908662	DM3K8VM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase B-raf (BRAF)	TTWCGQT	BRAF_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04543188) A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Pfzer
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2011).
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.
7	Clinical pipeline report, company report or official report of Ambit Biosciences.
8	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
9	National Cancer Institute Drug Dictionary (drug id 688029).
10	National Cancer Institute Drug Dictionary (drug id 680347).
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12	Clinical pipeline report, company report or official report of Exelixis (2011).